The relevance of gp100 as a tumor-rejection antigen is also supported by survival benefit and FDA approval of treating metastatic uveal melanoma with tebentafusp, a bispecific T cell engager built on an enhanced T cell receptor binding gp100280-28826–28. Here, PMEL is linked to neoplasm.